When clinicians evaluate treatment options for refractory or relapsed peripheral T-cell lymphoma (R/R-PTCL), choosing between an allogeneic or autologous hematopoietic stem cell transplant involves balancing long-term disease control against immediate treatment risks. According to a systematic review and meta-analysis, both procedures offer comparable overall and progression-free survival rates, but they carry distinct safety profiles.
Survival Outcomes in Peripheral T-Cell Lymphoma Trials
The systematic review evaluated 30 clinical trials and retrospective studies comprising 1,765 patients diagnosed with R/R-PTCL to compare the effectiveness of the two transplant modalities. Researchers divided the cohort, with 880 patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) and 885 patients receiving autologous HSCT, according to data extracted from studies published between January 12, 2001 and October 1, 2020. The analysis revealed that 3-year overall survival (OS) reached 50% for the allogeneic group and 55% for the autologous group. Progression-free survival (PFS) at three years showed similar parity, recorded at 42% for allogeneic recipients and 41% for autologous recipients. Five-year follow-up data maintained these comparable trends, with overall survival registering at 54% for allogeneic transplants and 53% for autologous transplants, while progression-free survival stood at 48% and 40%, respectively.
Safety Profiles and Transplant-Related Mortality
While survival curves for both procedures overlap significantly, safety data demonstrates a stark divergence in transplant-related mortality (TRM) between the two approaches. According to the meta-analysis data, the 3-year transplant-related mortality reached 32% for patients who underwent allogeneic HSCT. In sharp contrast, patients undergoing autologous HSCT experienced a 3-year transplant-related mortality of just 7%.
Clinical Implications for Rare Lymphoma Subtypes
Peripheral T-cell lymphomas represent a rare and clinically heterogeneous group of non-Hodgkin lymphomas characterized by aggressive behavior and generally poor prognoses. The primary clinical subtypes include peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma, and natural killer/T-cell lymphoma. Standard frontline therapies modeled on aggressive B-cell lymphoma regimens frequently fail in these patients, resulting in high rates of primary refractory disease and early relapse. The meta-analysis concludes that while allogeneic HSCT was associated with specific survival benefits, its higher toxicity profile requires clinicians to carefully weigh immediate safety against long-term disease eradication when selecting therapy for relapsed patients.
Related reading